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Enhancing the radiosensitivity of cancer cells is one of the most important tasks 
in clinical radiobiology. Endocrine therapy and radiotherapy are two cancer 
treatment modalities which are often given together in patients with locally-
advanced breast cancer and positive hormone-receptor status. Oncostatic 
actions of melatonin are relevant on estrogen-dependent mammary tumors. In 
the present study, we wanted to evaluate the effects of the combination of 
ionizing radiation and melatonin on proteins involved in estrogen biosynthesis in 
breast cancer cells. We demonstrated a role of melatonin in mediating the 
sensitization of human breast cancer cells to the ionizing radiation by 
decreasing around a 50% the activity and expression of proteins involved in the 
synthesis of estrogens in these cells. Thus, melatonin pretreatment before 
radiation reduces the amount of active estrogens at cancer cell level. Melatonin 
1 nM induced 2-fold change in p53 expression as compared to radiation alone. 
The regulatory action of melatonin on p53 could be a link between melatonin 
and its modulatory action on sensitivity of breast cancer cells to ionizing 
radiation. These findings may have implications for designing clinical trials using 
melatonin and radiotherapy.  
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Melatonin is the main secretory product of the pineal gland that 
participates in the regulation of important physiological and pathological 
processes, such as the regulation of neoplastic cell growth. Oncostatic actions 
of melatonin are relevant on tumors corresponding to the mammary gland and 
especially on estrogen-dependent mammary tumors [1-6]. Evidence from in vivo 
studies on animal models and in vitro studies on breast cancer cell lines 
supports the hypothesis that melatonin’s oncostatic effects on hormone-
dependent mammary tumors are mainly dependent on its ability to interact with 
the estrogen-signalling pathway [5,7]. At the mammary tumor cell level, 
melatonin interferes with the estrogen receptor, modulates estrogen binding, 
DNA-binding, and transcriptional activity, and counteracts the effects of 
estrogens, thus behaving as a selective estrogen receptor modulator. 
Melatonin, at physiological concentrations, is also able to modulate the 
synthesis and transformation of androgens and biologically active estrogens in 
human breast cancer cells, through the inhibition of aromatase, sulfatase and 
17β-hydroxysteroid dehydrogenase type 1 activity and expression, and the 
stimulation of sulfotransferase activity and expression, enzymes involved in the 
estradiol formation in breast cancer cells, thus behaving as a selective estrogen 
enzyme modulator [8-10]. 
The identification of estrogen’s central role in mammary carcinogenesis 
has led to investigation of estrogen pathways as major targets for breast cancer 
therapy. Breast-conserving surgery, radiotherapy for the affected breast, and 
adjuvant hormone therapy using antiestrogens, like tamoxifen, or aromatase 
inhibitors, like letrozol, are standard treatments for postmenopausal early breast 
cancer patients with hormone receptor-positive tumors [11,12]. Radiotherapy is 
considered a standard treatment option after surgery and adjuvant endocrine 
therapy is also universally used [11]. Timely initiation of radiation therapy is 
critical and contributes to a good recovery. Tamoxifen and letrozole are the 
current first-line endocrine therapy drugs. Tamoxifen, a selective estrogen 
receptor modulator, has provided a significant improvement in both local control 
and global survival rates [11,13]. Nowadays, it is estimated that tamoxifen may 
reduce the annual breast cancer death rate by 31% in estrogen receptor-
positive mammary tumors [13,14]. In vivo studies have shown a synergistic 
effect of concurrent antiestrogen treatment and radiotherapy on tumor cells [12-
14]. Aromatase inhibitors of third generation, which were introduced in the late 
1990s, have proven to be superior to tamoxifen for postmenopausal patient 
[15]. Although limited data on the use of aromatase inhibitors with radiotherapy 
are available, Azria et al. [16] described that letrozole, a non-steroid selective 
aromatase inhibitor, sensitizes breast cancer cells to ionizing radiation and 
Ishitobi et al. [17] described that the administration of aromatase inhibitors after 
and concurrently with radiotherapy in patients with breast cancer are both 
reasonable treatment options.  
Since melatonin has both antiestrogen and antiaromatase properties 
[4,5,8], we thought about the possibility that melatonin may regulate the 
sensitivity of human breast cancer cells to radiotherapy. Recently, our group 
demonstrated that melatonin pretreatment before radiation sensitizes breast 
cancer cells to the ionizing effects of radiation by decreasing cell proliferation, 
inducing cell cycle arrest and downregulating proteins involved in double-strand 
DNA break repair [18]. In the present study we investigated its effects on 
radiated human breast cancer cells by regulating proteins involved in estrogen 
biosynthesis. 
  
2. Materials and methods 
2.1. Cells and culture conditions 
 MCF-7 human breast cancer cells were purchased from the American 
Tissue Culture Collection (Rockville, MD, USA). They were maintained as 
monolayer cultures in 75 cm2 plastic culture flasks in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma-Aldrich, Madrid, Spain) supplemented with 
10% fetal bovine serum (FBS) (Biowest, Nuaille, France), penicillin (20 units/ml) 
and streptomycin (20 μg/ml) (Sigma-Aldrich, Madrid, Spain) at 37ºC in a humid 
atmosphere containing 5% CO2. 
  
2.2. Ionizing radiation treatment 
 MCF-7 cells were exposed to X irradiation using a model YXLON SMART 
200 tube (Yxlon International, Hamburg, Germany) at room temperature. Based 
in a previous study [18], we used 8 Gy radiation as the optimal radiation dose. 
The radiation was delivered as a single dose of 8 Gy in an 11.5 cm x 8.5 cm 
field size, 96-multiwell plates, at a dose rate of 0.92 Gy/min. The source-half-
depth distance was initially calculated to obtain a constant dose rate of 0.92 
Gy/min. Control cells were removed from the incubator and were place for the 




2.3. Measurement of cellular proliferation and cytotoxicity 
Cells were initially cultured for 24 h in DMEM supplemented with 0.5% 
dextran-charcoal stripped FBS (csFBS) and then media were replaced by fresh 
ones with 10% FBS and containing either 1 mM, 10 µM or 1 nM melatonin 
(Sigma-Aldrich, Madrid, Spain) and/or vehicle (ethanol at a final concentration 
lower than 0.0001%). Plates were incubated at 37ºC for 1 week in these media. 
Then, cells were seeded into 96-multiwell plates at a density of 8 x 103 cells per 
well in DMEM supplemented with 10% FBS and incubated at 37ºC for 24 h to 
allow for cell attachment before irradiation. After irradiation cells were cultured 
for 6 days. Cell proliferation was measured by the MTT [3(4,5dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] method [19], reading absorbance at 
570 nm in a microplate reader (Labsystems Multiskan RC 351, Vienna, VA, 
USA). MTT was obtained from Molecular Probes Inc. (Eugene, OR, USA).  
The effect of melatonin pretreatment before radiation on cellular survival 
was measured in a clonogenic assay. Control and melatonin (1 nM, 10 µM or 
1 nM) pretreated (a week) MCF-7 cells were cultured in a bilayer soft-agar 
system modified from that described by Hamburger and Salmon [20,21]. Briefly, 
the bottom layer consisted of DMEM enriched with FBS, penicillin (20 units/ml) 
and streptomycin (20 μg/ml). A 3% suspension of hot agar (70-75⁰C) was 
added to the enriched DMEM to make a final concentration of 0.5% agar. One 
ml of the resultant suspension (40-42⁰C) was then dispensed into a 35-mm2 
petri dish and allowed to cool to room temperature. The upper layer consisted of 
the same medium as the bottom layer and 3% agar was added to make a final 
concentration of 0.6%. Plating was performed by aspirating 0.5 ml of the cell 
suspension (1.75 x 105 viable cells) followed by 0.5 ml of the upper layer 
suspension (40-42⁰C) and dispensing the 1 ml on top of the lower layer. Cells 
were then incubated at 37⁰C with 5% CO2 and 100% humidity. Then, cells were 
exposed to 8 Gy irradiation and colonies > 150 µm were stained with crystal 
violet and counted 10 days after plating. The survival fraction was calculated 
according to the percentage of survival fraction of control non-radiated cells. 
   
2.4. Measurement of cellular aromatase activity   
Aromatase activity in MCF-7 cells was measured by the tritiated water 
release assay which is based on the formation of tritiated water during 
aromatization of a labeled androgenic substrate such as [1β-3H(N)]-androst-4-
ene-3,17-dione [22]. Control and melatonin (1 nM, 10 µM or 1 nM) pretreated (a 
week) MCF-7 cells were seeded into six-well plates at a density of (1.5 x 105 
cells / well) in DMEM supplemented with 10% FBS, 20 units/ml penicillin and 20 
µg/ml streptomycin and incubated at 37ºC for 24 h in a humid atmosphere 
containing 5% CO2, to allow for cell attachment before irradiation. Then, cells 
were irradiated and after 24 hours, media were aspirated and changed to 
serum-free media supplemented with 0.5% csFBS and containing the labeled 
substrate 300 nM [1β-3H(N)]-androst-4-ene-3,17-dione (NEN Life Science 
Products, Boston, MA, USA) (75-80 Ci/nM). After 24 hours, six-well plates were 
placed on ice for 15 min to condense any water vapor and media were 
transferred to tubes containing 0.25 ml ice-cold 30% tricholoroacetic acid (w/v), 
vortexed and centrifuged at 1700 g for 20 min. The supernatants were extracted 
with chloroform, vortexed and centrifuged at 1700 g for 20 min. The resulting 
aqueous supernatants were adsorbed with 10% dextran-coated charcoal 
(Sigma-Aldrich, Madrid, Spain), vortexed, centrifuged at 1700 g for 20 min. and 
the supernatants were added to vials with scintillation cocktail and counted in a 
beta counter (Beckman LS 6000 IC, Fulleton, CA, USA). The amount of 
radioactivity measured in [3H]-water was corrected by substracting the blank 
values from each sample, obtained by incubating dishes containing medium 
with the tritiated androgen but no cells. The values were also corrected by 
taking into account the fractional retention of tritium in medium water throughout 
the processing, utilizing parallel dishes containing medium plus known amounts 
of [3H]-water (NEN Life Science Products, Boston, MA, USA) through incubation 
and assay. The fractional retention of tritium in medium water throughout the 
incubation and processing of samples was always higher than 85%. 
 
2.5. Measurement of steroid sulfatase (STS) activity 
 STS activity in MCF-7 cells was assayed by the formation of estrone from 
a labelled substrate ([6,7-3H(N)]-estrone sulfate ammonium salt) [23]. Control 
and melatonin (1 nM, 10 µM or 1 nM) pretreated (a week) MCF-7 cells were 
seeded into six-well plates at a density of (1.5 x 105 cells / well) in DMEM 
supplemented with 10% FBS, 20 units/ml penicillin and 20 µg/ml streptomycin 
and incubated at 37ºC for 24 h in a humid atmosphere containing 5% CO2, to 
allow for cell attachment before irradiation. Then, cells were irradiated and after 
24 hours, media were aspirated and replaced with fresh ones (1 ml per plate) 
containing 5 pM [6,7-3H(N)]-estrone sulfate ammonium salt (NEN Life Science 
Products, Boston, MA, USA) (57.3 Ci / mM). After 24 h of incubation, culture 
dishes were placed on ice for 15 min to condense any water vapour and the 
media were transferred to tubes containing 5 ml of toluene, vortexed and 
centrifuged at 1000xg for 10 min. The resulting organic phase was added to 
vials with scintillation cocktail and counted in a beta counter. The amount of 
radioactivity measured in the [3H]-toluene was corrected by subtracting the 
blank values from each sample, obtained by incubating dishes containing 
medium but no cells with the tritiated estrone. The values were also corrected 
by taking into account the fractional retention of tritium in medium water 
throughout the procedure of incubation and processing, utilizing parallel dishes 
containing medium plus known amounts of [3H] estrone (NEN Life Science 
Products, Boston, MA, USA) through incubation and assay. The fractional 
retention of tritium in medium water throughout the incubation and processing of 
samples was always higher than 92%. 
 
2.6. Measurement of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) 
activity 
 Activity of 17β-HSD1 was assayed in MCF-7 cells by the formation of E2 
from a labelled substrate [2,4,6,7-3H(N)]-estrone [24]. Control and melatonin 
(1 nM, 10 µM or 1 nM) pretreated (a week) MCF-7 cells were seeded into six-
well plates at a density of (1.5 x 105 cells / well) in DMEM supplemented with 
10% FBS, 20 units/ml penicillin and 20 µg/ml streptomycin and incubated at 
37ºC for 24 h in a humid atmosphere containing 5% CO2, to allow for cell 
attachment before irradiation. Then, cells were irradiated and after 24 hours, 
media were aspirated and changed for fresh ones (1 ml per plate) containing 
2 nM [2,4,6,7-3H(N)]-estrone (NEN Life Science Products, Boston, MA, USA) 
(100 Ci / mM). After 30 min of incubation, the media were transferred to tubes 
containing 4 ml of diethyl ether, vortexed and centrifuged at 800xg for 5 min. 
The aqueous phase was frozen and the resulting organic phase was decanted, 
evaporated in tubes containing 50 µg of estradiol. The residue was 
resuspended in diethyl ether and separated by TLC using 
dichloromethane/ethyl acetate (4:1; v/v). Once the spots had been visualised, 
excised and eluted with methanol, they were counted in a liquid scintillation 
counter. Values were corrected for blanks and tritium recovery (higher than 
82%) as described for STS activity. 
  
2.7. Measurement of mRNA expression of STS, 17β-HSD1, aromatase, p53 
and aromatase promoter regions pI.3, pII and pI.7 gene expression 
Expression of the mRNA from different enzymes (aromatase, STS and 
17β-HSD1), p53 mRNA expression and aromatase mRNA promoter regions 
pI.3, pII and pI.7 expression in MCF-7 cells were carried out by real-time 
reverse transcription (RT-PCR) after incubation of control and melatonin (1 nM, 
10 µM or 1 nM) pretreated cells for 6 h after irradiation. The total cellular RNA 
was isolated from MCF-7 cells and purified with the Nucleospin RNA II kit 
(Macherey-Nagel. GmbH & Co. Düren, Germany) following the manufacturer’s 
instructions. The absorbance ratio A260nm/A280nm was greater than 1.9. For 
cDNA synthesis, 1 µg of total RNA was denaturated at 65ºC for 10 min and 
reverse-transcribed for 30 min at 45ºC with the Tetro cDNA synthesis Kit 
(Bioline, London, UK) in a final volume of 20 µl in the presence of 500 ng of 
oligo (dT)12–18 primer. Real time PCRs were performed in an MX3005 
(Agilent, CA, USA) using Brilliant® III Ultra-Fast SYBR® Green QPCR Master 
Mix (Agilent Technologies, CA, USA) following the manufacturer’s instructions. 
The sets of human oligonucleotides (Sigma Genosys Ltd., Cambridge, UK) 
used as primers are indicated in table I. Ribosomal subunit (S14) mRNA 
expression was used for normalization. Amplifications were initiated by 1 cycle 
at 95ºC for 3 min and then performed for 40 cycles for quantitative analysis 
using the following temperature profile: 95ºC for 20 sec (denaturation); 60ºC for 
20 sec (annealing/extension), setting the instrument to detect and report 
fluorescence at each cycle during the 60ºC annealing/extension step. Each 
reaction was run in triplicate. Melting curves were performed by using 
dissociation curve to verify that only a single product with no primer-dimers was 
amplified. For the primers used there were no differences between transcription 
efficiencies, and the fold-change in each sample was calculated by the 2-∆∆Ct 
method [25].  
 
2.8. Statistical analysis 
The data are expressed as the mean ± standard errors of the mean (SEM) 
of six independent experiments. Statistical differences between groups were 
analyzed by using one way analysis of variance (ANOVA), followed by the 




3.1. Effects of ionizing radiation and melatonin on cell proliferation and 
cytotoxicity 
With radiation alone, the MCF-7 cell proliferation decreased in a dose-
dependent manner and for 8 Gy radiation, the inhibition of cell proliferation was 
40% with respect to control non-radiated cells (Fig. 1A). Treatment with 
physiologic concentrations of melatonin (1 nM) for 7 days before radiation led to 
a significantly (p<0.001) higher decrease in cell proliferation in comparison with 
control radiated cells. Pretreatment with pharmacologic concentrations of 
melatonin (1 mM and 10 µM) also induced a marked decrease in cell 
proliferation but was less effective than pretreatment with physiologic 
concentrations (1 nM) (Fig. 1A).  
Figure 1B shows the effect of ionizing radiation and melatonin 
pretreatment on cytotoxicity. The survival fraction after 8 Gy irradiation dose 
was reduced 84% with respect to non-radiated cells. Pretreatment with 
melatonin (1 mM, 10 µM and 1 nM) led to a significantly biggest decline in 
survival rates, with melatonin concentrations (1 mM) being the most effective in 
decrease the survival fraction (50 % of reduction when compared to control 
radiated cells). 
 
3.2. Effects of ionizing radiation and melatonin on aromatase activity and 
expression and aromatase promoter regions pI.3, pII and pI.7 expression   
With 8 Gy radiation alone, aromatase activity was significantly (p<0.001) 
decreased by 40%. Treatment with physiologic concentrations of melatonin (1 
nM) for 7 days before radiation led to a significantly higher decrease in 
aromatase activity (Fig. 2A) (70% of reduction when compared to control non-
radiated cells). Pharmacologic concentrations of melatonin (1 mM) were also 
effective to reduce (p<0.001) the aromatase activity of breast cancer cells 
(Fig. 2A). With the aim of determining whether the inhibitory effect of melatonin 
on aromatase activity is due to the downregulation of aromatase expression, we 
irradiated control and melatonin pretreated MCF-7 cells and after 6 h total RNA 
was isolated to perform real-time quantitative PCR with specific primers for 
human aromatase. Radiation (8 Gy) alone significantly decreased (p<0.001) in 
a half aromatase RNA expression in MCF-7 cells (Fig. 2B). Physiologic 
concentrations of melatonin pretreatment before radiation resulted in a 
significantly higher decreased in aromatase mRNA expression (50% of control 
radiated cells). Very high pharmacologic concentrations of melatonin (1 mM) 
were also effective to reduce (p<0.001) the aromatase mRNA expression of 
breast cancer cells (Fig. 2B). 
To determine the promoters involved in the melatonin control of aromatase 
expression, we used competitive RT-PCR to amplify each of the promoter-
specific transcripts from RNA extracted from MCF-7 cells. As shown in Figure 3, 
melatonin 1 nM exerted a significant (p<0.001) inhibition in aromatase 
expression that is specific to the aromatase promoters I.3, pII and pI.7. Higher 
concentrations of melatonin were also effective to reduce (p<0.001) the 
aromatase expression specific to the aromatase promoters I.3, pII and pI.7 
(Fig. 3). 
 
3.3. Effects of ionizing radiation and melatonin on STS activity and expression   
In a second set of experiments, the effects of melatonin treatment before 
radiation on the STS activity and mRNA expression were studied. With radiation 
alone a significant (p<0.001) decrease in STS activity (30% less activity), the 
enzyme responsible for the conversion of estrogens to the less potent sulfate 
conjugated forms, was observed (Fig. 4A). When MCF-7 cells were pretreated 
with physiologic concentrations of melatonin (1 nM) the inhibition of STS activity 
was 50% with respect to control radiated cells. Pretreatment with higher 
concentrations of melatonin was also effective to reduce (p<0.001) the STS 
activity (Fig. 4A).  
Radiation alone significantly decreased the expression of STS by 25%. 
Treatment with melatonin for 7 days before radiation led to a significantly 
greater decrease in STS mRNA expression compared with radiation alone and 
doubled the inhibition (Fig. 4B). 
 
3.4. Effects of ionizing radiation and melatonin on 17β-HSD1 activity and 
expression   
Next, the effects of melatonin treatment before radiation on the 17β-HSD1 
activity and mRNA expression were studied. With radiation alone a significant 
(p<0.001) decrease in 17β-HSD1 activity, the enzyme responsible for the 
conversion of the relatively inactive estrone to the most potent 17β-estradiol, 
was observed (Fig. 5A). When MCF-7 cells were pretreated with physiologic 
concentrations of melatonin (1 nM) the inhibition of 17β-HSD1 activity was twice 
as much as that of control radiated cells. Pretreatment with higher 
concentrations of melatonin (1 mM) was even more effective to reduce 
(p<0.001) the 17β-HSD1 activity (Fig. 5A).  
Radiation alone significantly also decreased by 20% the expression of 
17β-HSD1. Treatment with melatonin for 7 days before radiation led to a 
significantly greater decrease in 17β-HSD1 mRNA expression compared with 
radiation alone (Fig. 5B), with physiologic melatonin concentrations (1 nM) 
being the most effective in decrease the 17β-HSD1 mRNA expression (a half of 
expression than radiated cells). 
 
3.5. Effects of ionizing radiation and melatonin on p53 mRNA expression   
With 8 Gy radiation alone, the expression of mRNA p53 increased two-
times (p<0.001). Pretreatment with physiologic concentrations of melatonin 
(1 nM) for 7 days before radiation led to a significantly higher increase in p53 
mRNA expression, three-times as big as control non-radiated cells (Fig. 6). 
Higher concentrations of melatonin (10 µM) were also effective to increase 
(p<0.001) p53 mRNA expression of breast cancer cells (Fig. 6).  
 
4. Discussion 
Endocrine therapy and radiotherapy are two cancer treatment modalities which 
are often given together in patients with locally-advanced breast cancer and 
positive hormone-receptor status. Enhancing the radiosensitivity of cancer cells 
whilst preserving the health of normal cells is one of the most important tasks in 
clinical radiobiology. Preclinical models have described changes in tumor cell 
kinetics and reduced tumor cell death with concurrent antiestrogen treatment 
and radiotherapy [12]. Preliminary results from simultaneous treatment with 
aromatase inhibitors and radiation also indicate that this combination of 
endocrine and radiation therapy could enhance cytotoxicity and improve tumor 
response [12,13]. Melatonin, the principal hormone synthesized and produced 
in the pineal gland, has been extensively reported as an important inhibitor of 
neoplastic proliferation, especially on tumors of the mammary gland, most of 
which are estrogen-responsive [1-4,26-28]. At cancerous cellular level, 
melatonin, on one hand, interferes with the estrogen-dependent pathways and 
partially abolishes the effects of estrogens, thus behaving as a selective 
estrogen receptor modulator and, on the other hand, is also able to modulate 
both the catalytic activity and gene expression of some enzymes participating in 
the local synthesis of estrogens in human breast cancer and also in proximal 
vascular endothelial and adipose cells, thus behaving as a selective estrogen 
enzyme modulator [1,7,27-33]. Our group have described that melatonin, in 
vitro, could act as a radiosensitizer. Treatment for one week before radiation 
with melatonin, enhances the sensitivity of breast cancer cells to the ionizing 
effects of radiation by decreasing cell proliferation, inducing cell cycle arrest and 
downregulating proteins involved in double-strand DNA break repair [18]. In the 
present study, we wanted to evaluate in vitro the effects of the combination of 
ionizing radiation and melatonin on proteins involved in estrogen biosynthesis in 
malignant epithelial cells. Our results demonstrate that a combined treatment 
with melatonin and ionizing radiation could result in cooperative enhancement 
of cytotoxic and radiosensitizing effects in human breast cancer cells and that 
this enhancement of the radiosensitivity is associated with the modulation of 
enzymes involved in estrogen synthesis. Pretreatment of human breast cancer 
cells with melatonin one week before radiation led to a significantly higher 
decrease of MCF-7 cell proliferation (MTT assay) and survival fraction 
(clonogenic assay) compared with radiation alone. Those findings confirm 
previous results of our group [19] suggesting that the addition of melatonin 
promotes inhibition of cell proliferation and enhances the effects of radiation. 
Similarly to our findings, the sensitivity and dose-response characteristics of 
breast cancer cells to the inhibitory effect of melatonin are altered by the growth 
of cells in an anchorage-dependent culture as compared to anchorage-
independent growth [1,2,21]. In proliferation assays (monolayer cultures) 
melatonin concentrations close to 1 nM, similar to those found in the serum of 
most mammals during the night, are the most effective [1,2]. However, in the 
clonogenic assay, in which cancer cells grow suspended in a semisolid medium 
without attaching to the plate, pharmacological concentrations produce a 
maximal inhibition [21]. Cell attachment modify the sensitivity of MCF-7 cells 
towards melatonin. In addition, ionizing radiation decreased aromatase activity 
and expression, the enzyme that transform androgens into estrogens in 
malignant cells. Melatonin pretreatment before radiation induced a higher 
decrease in aromatase activity and expression. In disease-free breast tissue, 
aromatase is primarily expressed in adipose stromal fibroblasts via the relatively 
weak promoter I.4 [34,35]. However, in breast cancer tissue, aromatase 
promoters I.3 and II are activated, leading to a marked increase in aromatase 
expression in malignant epithelial cells and adipose fibroblasts. Both promoters 
are considered the major drivers of aromatase expression in breast cancer and 
surrounding adipose tissue, accounting for 80-90% of total aromatase 
expression [34,35]. The present study demonstrates that melatonin-dependent 
regulation of aromatase gene expression occurs mainly through a 
downregulation of gene expression of the both major specific aromatase 
promoter regions pII and pI.3 in breast cancer cells. Ionizing radiation inhibited 
aromatase promoter I.3 and II mediated expression and melatonin pretreatment 
enhanced the down-regulatory action on aromatase promoters I.3 and II 
induced by radiation. Aromatase pII was the most abundantly expressed 
compared to pI.3 and melatonin inhibitory action was more potent on this 
aromatase promoter region pII. Also, melatonin further enhanced the decrease 
triggered by radiation of the aromatase promoter region pI.7 expression, a novel 
breast cancer-associated aromatase promoter mainly active in vascular 
endothelial cells but also present in malignant epithelial cells [36]. Besides this 
melatonin down-regulatory effect on aromatase activity and expression and on 
the two main promoters driving aromatase expression in breast cancer, in our 
study, melatonin also modulates the activity and expression of the STS and 
17β-HSD1. The estrone sulfatase pathway is the major route of estrogen 
formation in breast tumors and the estrogen sulfatase activity is 40-500 times 
higher than aromatase activity in breast cancer tissues [37,38]. Radiation alone 
decreased STS and 17β-HSD1 activity and expression and melatonin 
pretreatment for one week before radiation enhanced the decrease in STS and 
17β-HSD1 activity and expression induced by ionizing radiation. Thus, 
melatonin pretreatment by down-regulating aromatase, STS and 17β-HSD1 
might reduce active estrogens levels at tumoral cell level. 
The tumour suppressor p53 is a central factor for the maintenance of 
genome stability and, consequently, for the suppression of cancer [39]. p53 is 
upregulated and activated by genotoxic stress, like ionizing radiation, and 
induces a transcriptional program with effectors promoting apoptosis, cell cycle 
arrest, senescence and DNA repair [40,41]. There is growing evidence for a 
direct role of p53 in the fidelity control of DNA repair to ensure error-free DNA 
double-strand breaks repair and, therefore, to suppress detrimental genome 
rearrangements that drive cancer [39,42]. p53 modulates DNA repair and may 
assist in the down-regulation of inappropriate recombination in particular 
through direct interaction and inhibition of repair proteins such as RAD51 [43]. 
In addition it has been recently demonstrated that p53 is a negative regulator of 
aromatase in the breast [44]. Radiation alone increased p53 expression. 
Pretreatment of breast cancer cells with physiologic concentrations of melatonin 
before radiation led to a greater increase of p53 expression. The up-regulation 
of the expression of p53 and p21WAF1 proteins induced by melatonin has been 
suggested as an important mechanism through which this indolamine produces 
antiproliferative effects in human breast cancer cells [45]. Since melatonin 
pretreatment before radiation sensitizes breast cancer cells to the ionizing 
effects of radiation by decreasing cell proliferation, inducing cell cycle arrest, 
downregulating proteins involved in double-strand DNA break repair and 
estrogen biosynthesis, and p53 promotes cell cycle arrest, DNA repair and 
aromatase down-regulation, the regulatory action of melatonin on p53 could be 
a link between melatonin and its modulatory action on sensitivity of breast 
cancer cells to the ionizing radiation. 
In summary, the findings present herein suggest that melatonin 
enhancement of the radiosensitivity of human breast cancer cells is associated 
with the modulation of proteins involved in estrogen biosynthesis. 
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Fig. 1.  Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and ionizing 
radiation on MCF-7 cell proliferation and survival fraction. (A) Control and 
melatonin pretreated MCF-7 cells for a week were seeded into 96-multiwell 
plates in DMEM supplemented with 10% FBS and incubated at 37ºC for 24 h. 
Then, cells were irradiated, cultured for 6 days and cell proliferation was 
measured by the MTT method. (B) Control and melatonin pretreated MCF-7 
cells for a week were cultured in a in a bilayer soft-agar system in DMEM 
supplemented with 10% FBS and agar. After 24 h of incubation at 37ºC, cells 
were irradiated, cultured for 10 days and colonies > 150 µm were stained and 
counted. Survival fraction was calculated as described in material and methods. 
Data are expressed as the percentage of the control non-radiated group 
(mean ± SEM). a, p<0.001 vs control non-radiated cells; b, p<0.001 vs control 
radiated cells; c, p<0.001 vs 1 mM melatonin; d, p<0.001 vs 10 µM melatonin. 
 
Fig. 2.  (A) Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and 
ionizing radiation on aromatase activity of MCF-7 cells. Control and melatonin 
pretreated MCF-7 cells for a week were seeded into six-well plates in DMEM 
supplemented with 10% FBS. After 24 h cells were irradiated and 24 h later 
media were aspirated and changed to serum-free media supplemented with 
0.5% csFBS and tritiated androstenedione. Aromatase activity was determined 
after 24 h of incubation, as described in Material and methods. (B) Effects of 
melatonin pretreatment (1 mM, 10 µM or 1 nM) and ionizing radiation on the 
expression of mRNA aromatase in MCF-7 cells. Aromatase mRNA expression 
was carried out by RT-PCR after incubation of control and melatonin (1 nM, 
10 µM or 1 nM) pretreated cells for 6 h after irradiation. Data are expressed as 
the percentage of the control non-radiated group (mean ± SEM). a, p<0.001 vs 
control non-radiated cells; b, p<0.001 vs control radiated cells; c, p<0.001 vs 1 
mM melatonin. 
    
Fig. 3.  Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and ionizing 
radiation on aromatase promoter regions pI.3 (A), pII (B) and pI.7 (C) 
expression in MCF-7 cells. Control and melatonin pretreated cells were cultured 
for 6 h after irradiation. Total mRNA was extracted from MCF-7 cells and 
reverse transcribed. cDNA was subjected to PCR using specific primers for 
aromatase promoter I.3, II and I.7 or S14. Data are expressed as the 
percentage of the control non-radiated group (mean ± SEM). a, p<0.001 vs 
control non-radiated cells; b, p<0.001 vs control radiated cells; c, p<0.01 vs 
control radiated cells; d, p<0.001 vs 1 mM melatonin; e, p<0.001 vs 10 µM 
melatonin. 
    
Fig. 4.  (A) Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and 
ionizing radiation on sulfatase activity of MCF-7 cells. Control and melatonin 
pretreated MCF-7 cells for a week were seeded into six-well plates in DMEM 
supplemented with 10% FBS. After 24 h cells were irradiated and 24 h later 
media were aspirated and changed to serum-free media containing tritiated 
estrone sulfate ammonium salt. Sulfatase activity was determined after 24 h of 
incubation, as described in Material and methods (B) Effects of melatonin 
pretreatment (1 mM, 10 µM or 1 nM) and ionizing radiation on sulfatase mRNA 
expression in MCF-7 cells. Control and melatonin pretreated cells were cultured 
for 6 h after irradiation and total mRNA was isolated from cells and reverse 
transcribed. cDNA was subjected to PCR using specific primers for sulfatase or 
S14. Data are expressed as the percentage of the control non-radiated group 
(mean ± SEM). a, p<0.001 vs control non-radiated cells; b, p<0.001 vs control 
radiated cells; c, p<0.01 vs 1 mM melatonin; d, p<0.001 vs 10 µM melatonin. 
 
Fig. 5.  (A) Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and 
ionizing radiation on 17β-HSD1 activity in MCF-7 cells. Control and melatonin 
pretreated MCF-7 cells for a week were seeded into six-well plates in DMEM 
supplemented with 10% FBS. After 24 h cells were irradiated and 24 h later 
media were aspirated and changed to serum-free media containing tritiated 
estrone. 17β-HSD1 activity was determined after 30 min. of incubation, as 
described in Material and methods (B) Effects of melatonin pretreatment (1 mM, 
10 µM or 1 nM) and ionizing radiation on 17β-HSD1 mRNA expression in 
MCF-7 cells. Control and melatonin pretreated cells were cultured for 6 h after 
irradiation and total mRNA was isolated from cells and reverse transcribed. 
cDNA was subjected to PCR using specific primers for 17β-HSD1 or S14. Data 
are expressed as the percentage of the control non-radiated group (mean ± 
SEM). a, p<0.001 vs control non-radiated cells; b, p<0.001 vs control radiated 
cells; c, p<0.001 vs 1 mM melatonin. 
 
Fig. 6.  Effects of melatonin pretreatment (1 mM, 10 µM or 1 nM) and ionizing 
radiation on p53 mRNA expression in MCF-7 cells. Control and melatonin 
pretreated cells were cultured for 6 h after irradiation. Total mRNA was 
extracted from MCF-7 cells and reverse transcribed. cDNA was subjected to 
PCR using specific primers for p53 or S14. Data are expressed as the 
percentage of the control non-radiated group (mean ± SEM). a, p<0.001 vs 
control non-radiated cells; b, p<0.001 vs control radiated cells; c, p<0.001 vs 1 
mM melatonin; d, p<0.001 vs 10 µM melatonin. 
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